Multiple Bispecific Formats
CHO & HEK293 Expression
Dual-Binding Validated
SPR / BLI Characterization
GMP-Grade Available
Service Overview
Engineering Dual Specificity for Next-Generation Therapeutics
Bispecific antibodies represent a rapidly growing class of next-generation biologics, enabling simultaneous engagement of two distinct antigens or epitopes to achieve mechanisms of action impossible with conventional monospecific antibodies — including T-cell redirection, dual checkpoint blockade, dual receptor targeting, and conditional activation. ICDMO's bispecific antibody development service offers a comprehensive portfolio of formats supported by world-class protein engineering, recombinant expression, and biophysical characterization capabilities.
Our experienced scientists guide you from target pair selection and format strategy through construct engineering, expression optimization, purification, and rigorous characterization, accelerating your path from concept to IND-ready material.
8+
Bispecific Formats
95%+
Monomer Purity Spec
Partners
GMP Capability
Bispecific Formats
Supported Bispecific Architectures
We support a wide range of bispecific formats — IgG-like, fragment-based, and custom architectures — tailored to your MOA and CMC requirements.
What We Offer
Bispecific Design & Format Selection
▸Target pair analysis: antigen proximity, receptor stoichiometry, and desired mechanism of action
▸Format recommendation: IgG-like, BiTE, DART, DVD-Ig, CrossMab, or custom based on half-life, valency, and CMC requirements
▸Computational modeling of bispecific architecture and linker optimization
▸Affinity balancing strategy to ensure simultaneous dual engagement without steric clash
▸Immunogenicity in silico assessment of linker and junction sequences
Bispecific Antibody Construction
▸Gene synthesis of bispecific construct (codon-optimized for CHO or HEK293 expression)
▸Vector engineering for co-expression of two heavy chains + two light chains
▸Knobs-into-holes, charge pair, or CrossMab mutations introduced for correct heavy chain pairing
▸Common light chain strategy or separate light chain co-expression with chain pairing confirmation
▸Transient expression screening in HEK293 for rapid format validation before stable line generation
Production & Purification
▸Transient CHO or HEK293 expression: 0.1 mg to 500 mg scale
▸Stable CHO cell line development for GMP-grade manufacturing
▸Protein A capture → low-pH elution → secondary polishing (IEX or HIC)
▸Mispairing removal: Ion exchange chromatography to separate homo- from hetero-dimers
▸SEC-HPLC aggregate removal; final formulation in PBS or custom buffer
Bispecific Characterization
▸SDS-PAGE (reducing and non-reducing) confirming correct MW and chain pairing
▸SEC-HPLC monomer purity (>95% standard); native MS for intact molecular weight
▸Dual-target binding ELISA: simultaneous binding to both antigens confirmed
▸Affinity measurement by SPR (Biacore) or BLI (Octet) for each binding arm independently
▸Functional assay: T-cell killing (for BiTEs), receptor signaling blockade, or dual receptor internalization
▸In vitro stability: forced degradation, freeze-thaw, and thermal stability (DSF) studies
Key Advantages
Multi-Format Expertise
IgG-like, BiTE, DART, DVD-Ig, CrossMab, half-body exchange, and custom formats — all supported under one roof.
Validated Pairing Strategies
Knobs-into-holes, charge pairs, common light chain, and CrossMab strategies ensure correct heavy chain heterodimerization.
Comprehensive Characterization
Intact mass by native MS, dual-target ELISA, SPR/BLI kinetics for each arm, functional T-cell killing or receptor blocking assays.
Rapid Feasibility Turnaround
Transient HEK293 expression at small scale delivers initial bispecific material within 3–4 weeks for format validation.
GMP-Compatible Process
Stable CHO cell line development and GMP bioreactor manufacturing arranged through qualified partner facilities for IND-enabling and clinical-stage programmes.
One-Stop Therapeutic Pipeline
Seamlessly paired with upstream antibody generation, downstream ADC conjugation, and in vivo efficacy evaluation services.
Development Workflow
1
Target Pair Review & Format Strategy
Submit your two target antigens, desired MOA, and indication. Our antibody engineers assess pairing feasibility, recommend optimal bispecific format, and outline the full development plan.
2
Parental Antibody Sourcing or Development
Use your existing antibodies or engage ICDMO's antibody development service. Variable region sequences are analyzed for compatibility and any required humanization or affinity maturation identified.
3
Bispecific Construct Engineering
Gene synthesis of the complete bispecific construct. Knobs-into-holes or charge-pair mutations introduced. Common light chain or CrossMab design applied as appropriate. Sequence verified before expression.
4
Small-Scale Transient Expression & Screening
Transient transfection in HEK293 or CHO cells at 50–200 mL scale. SDS-PAGE and dual-ELISA screening to confirm bispecific format, pairing efficiency, and dual-binding activity.
5
Scale-Up Production & Purification
Scale-up in bioreactor or spinner flask. Multi-step chromatography purification. Monomer purity confirmed by SEC-HPLC. Mispaired homodimers removed by IEX. Final QC batch record prepared.
6
Comprehensive Characterization & Delivery
Full biophysical and functional characterization: SEC-HPLC, native MS, SPR/BLI binding kinetics for both arms, dual-ELISA, functional cytotoxicity or receptor blockade assay. CoA and data package delivered.
Service Process
1
Strategy Consultation
›
2
Construct Design
›
3
Expression & Screening
›
4
Scale-Up & Purification
›
5
Characterization & Delivery
Specifications & Timeline
Note: Bispecific antibody development timelines depend on target pair difficulty, format complexity, and expression optimization requirements. Contact us for a project-specific feasibility assessment and timeline estimate.
What Published Work Reports
The results below were published by independent groups and are cited to show what these computational approaches have achieved in the literature. They are not ICDMO project results, and outcomes vary substantially between targets, datasets and programmes. We do not promise comparable results for any particular project.
10- to 140-fold affinity improvements from computational design
Computational interface redesign produced a tenfold affinity improvement in cetuximab, reaching 52 pM, and a 140-fold improvement to 30 pM for an anti-lysozyme model antibody — improvements achieved by designing a small number of interface substitutions rather than by library selection.
Lippow, Wittrup & Tidor, Nature Biotechnology, 2007 ↗Interface models predict which substitutions help, with measurable accuracy
A 2024 study combining structural interface analysis with sequence-derived evolutionary information reported a predictive model for antibody–antigen interaction with an area under the curve of 0.83 and precision of 0.89 on held-out data, and experimentally confirmed a designed point mutation that improved affinity 2.5-fold to 2 nM. Typical computational maturation gains are modest per mutation, which is why a designed panel is measured rather than a single variant.
Experimental validation study, 2024 ↗What We Need From You
▸Sequences of both binding arms, with any structural or epitope information available
▸The intended mechanism, including whether simultaneous engagement of both targets is required
▸Valency, geometry, effector function and half-life requirements
▸Expression system and purification approach, since these constrain which formats are practical
▸Any existing bispecific constructs with their expression, pairing and stability results
How the Work Is Performed
▸Format evaluation across CrossMab, knob-into-hole, DuoBody-style, scFv fusion, tandem and DVD-Ig architectures
▸Structural modelling of each chain, of the assembled construct and of both antigen complexes
▸Chain pairing analysis with design of the interface mutations needed to enforce correct assembly
▸Linker and hinge design with conformational sampling to establish reach, span and flexibility
▸Ternary geometry modelling where the mechanism depends on bridging two cells or two receptors
▸Developability assessment per candidate format: aggregation, thermal stability and purification behaviour
What You Receive
▸Format recommendation with the candidate architectures compared against your requirements
▸Complete construct sequences including linkers, hinges and interface mutations
▸Structural models of the assembled molecule and of the antigen complexes
▸Chain mispairing risk assessment with the engineering solution applied and its rationale
▸Prioritised construction and testing plan across the designed constructs
Interpretation and Limitations
Modelling establishes geometric feasibility, assembly behaviour and stability risk. It does not predict functional potency, which depends on receptor density, signalling thresholds and cell biology that only cell-based assays resolve. Mispairing predictions indicate relative risk between designs rather than absolute expression outcomes. Construction, expression and functional testing are performed by your team or a partner.
Questions We Are Asked Before Scoping
Which bispecific format should we use?
It depends on the mechanism, the valency you need, the geometry required for engagement and your manufacturing platform. We compare the practical candidates against those constraints and state the trade-offs rather than defaulting to one architecture.
Can you model whether both arms can engage at once?
Yes. Span, linker flexibility and the geometry of both antigen complexes are modelled together, which is the most common reason a bispecific fails to work as intended despite both arms binding well in isolation.
We already have a construct that expresses poorly. Can you diagnose it?
Often. Poor expression in bispecifics usually traces to chain mispairing, interface instability or an aggregation-prone linker region. We model the construct and identify which of those is the likely cause.
Get a Custom Quote
Bispecific experts respond within 24 hours with a format strategy, feasibility assessment, and proposal.
Contact Us Online ConsultationStandard Deliverables
✓Sequence-verified expression plasmid
✓Purified bispecific antibody
✓SDS-PAGE (reducing & non-reducing)
✓SEC-HPLC monomer purity report
✓Dual-target binding ELISA
✓SPR/BLI binding kinetics (both arms)
✓Certificate of Analysis (CoA)
Why ICDMO?
8+ Bispecific Formats Modelled
CHO & HEK293 Expression
SPR / BLI Through Partners
GMP Through Qualified Partners
Design-to-Validation Planning